Stand strong against influenza with AFLURIA QUADRIVALENT
- Administer as a 0.25-mL dose for patients 6 through 35 months, and as a 0.5-mL dose for patients 36 months through 8 years as 1 or 2* doses
- Demonstrated immunogenicity in children and adults
- Demonstrated safety profile
- Produced through traditional egg-based manufacturing
Demonstrated safety profile of AFLURIA QUADRIVALENT
APPROVED FOR PERSONS 6 MONTHS OF AGE AND OLDER.
Proportion of subjects per age with any solicited local adverse reactions or systemic adverse effects within 7 days after administration of AFLURIA QUADRIVALENT.
The safety and efficacy of AFLURIA QUADRIVALENT in persons less than 6 months of age have not been established.
The PharmaJet® Stratis® Needle-Free Injection System is not approved as a method of administering AFLURIA QUADRIVALENT to persons less than 18 and greater than 64 years of age due to lack of adequate data supporting safety and efficacy in these populations.
Store AFLURIA QUADRIVALENT refrigerated at 2°C to 8°C (36°F to 46°F). Protect from light. Do not freeze. Discard if the vaccine has been frozen. Do not use it after expiration date.
